Complement Activation in Kidneys of Patients With COVID-19.
COVID-19
complement—immunological term
endothelial injury
kidney
lectin pathway activation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
Historique:
received:
14
08
2020
accepted:
22
12
2020
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Most patients who became critically ill following infection with COVID-19 develop severe acute respiratory syndrome (SARS) attributed to a maladaptive or inadequate immune response. The complement system is an important component of the innate immune system that is involved in the opsonization of viruses but also in triggering further immune cell responses. Complement activation was seen in plasma adsorber material that clogged during the treatment of critically ill patients with COVID-19. Apart from the lung, the kidney is the second most common organ affected by COVID-19. Using immunohistochemistry for complement factors C1q, MASP-2, C3c, C3d, C4d, and C5b-9 we investigated the involvement of the complement system in six kidney biopsies with acute kidney failure in different clinical settings and three kidneys from autopsy material of patients with COVID-19. Renal tissue was analyzed for signs of renal injury by detection of thrombus formation using CD61, endothelial cell rarefaction using the marker E-26 transformation specific-related gene (ERG-) and proliferation using proliferating cell nuclear antigen (PCNA)-staining. SARS-CoV-2 was detected by
Identifiants
pubmed: 33584662
doi: 10.3389/fimmu.2020.594849
pmc: PMC7878379
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
594849Informations de copyright
Copyright © 2021 Pfister, Vonbrunn, Ries, Jäck, Überla, Lochnit, Sheriff, Herrmann, Büttner-Herold, Amann and Daniel.
Déclaration de conflit d'intérêts
Author AS was employed by the company Pentracor GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Immunol. 2020 Jun;215:108450
pubmed: 32360516
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Cardiovasc Res. 2020 Dec 1;116(14):2177-2184
pubmed: 32750108
J Am Soc Nephrol. 2020 Sep;31(9):1959-1968
pubmed: 32680910
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Semin Nephrol. 2013 Nov;33(6):479-92
pubmed: 24161035
Immunol Rev. 2016 Nov;274(1):98-111
pubmed: 27782318
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
J Clin Invest. 2016 May 2;126(5):1911-25
pubmed: 27088797
J Exp Med. 1981 Sep 1;154(3):856-67
pubmed: 6912277
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Crit Care. 2020 Jun 16;24(1):346
pubmed: 32546191
J Am Soc Nephrol. 2020 Sep;31(9):1944-1947
pubmed: 32675304
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
J Allergy Clin Immunol. 2020 Jul;146(1):215-217
pubmed: 32417135
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):587-591
pubmed: 32723436
J Am Soc Nephrol. 2020 Aug;31(8):1683-1687
pubmed: 32371536
J Am Soc Nephrol. 2020 Sep;31(9):2158-2167
pubmed: 32727719
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4040-4047
pubmed: 32329881
Emerg Microbes Infect. 2015 May;4(5):e28
pubmed: 26060601
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Immunobiology. 2016 Oct;221(10):1068-72
pubmed: 27286717
Int J Mol Sci. 2020 May 05;21(9):
pubmed: 32380787
J Clin Invest. 2020 Aug 3;130(8):3950-3953
pubmed: 32459663
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Mol Immunol. 2010 Aug;47(13):2154-60
pubmed: 20542571
Expert Opin Biol Ther. 2007 Oct;7(10):1575-82
pubmed: 17916049
EBioMedicine. 2020 Aug;58:102925
pubmed: 32745993